Lung cancer is the leading cause of cancer death in the
|
|
- Allan Hampton
- 5 years ago
- Views:
Transcription
1 Arterial Invasion Predicts Early Mortality in Stage I Non Small Cell Lung Cancer Taine T. V. Pechet, MD, Shamus R. Carr, MD, Joshua E. Collins, BS, Herbert E. Cohn, MD, and John L. Farber, MD Division of Thoracic Surgery and Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania Background. A retrospective study was performed to evaluate the association between arterial invasion and survival in patients with stage I non small cell lung cancer. Methods. One hundred patients were identified who had undergone complete anatomic resection as definitive treatment for stage I non small cell lung cancer. The tumors were reviewed for the presence or absence of arterial invasion. Five-year survival data were obtained for all patients. Results. The 100 patients had an overall 5-year survival of 61%. There were 64 stage IA patients with a 62% 5-year survival and 36 stage IB patients with a 58% 5-year survival. The 39 patients identified with arterial invasion had a 38% 5-year survival compared with a 73% 5-year survival in the 61 patients without arterial invasion (p < 0.001), with an unadjusted hazard ratio of 3.5 (p < 0.001). Multivariate analysis by stage IA versus IB and by size greater or less than 2 cm demonstrated hazard ratios of 3.5 and 4.0, respectively (p < 0.001). This difference was independent of demographic characteristics, tumor type, or grade. Subgroup analysis revealed a hazard ratio of 5.8 in patients with stage IA non small cell lung cancer (p < 0.001) and 19.8 in patients with tumors < 2cm(p 0.006). Conclusions. Arterial invasion is present in a substantial percentage of patients with stage I non small cell lung cancer and is adversely associated with survival. (Ann Thorac Surg 2004;78: ) 2004 by The Society of Thoracic Surgeons Lung cancer is the leading cause of cancer death in the Western hemisphere [1]. Regardless of recent treatment advances, survival for all patients remains near 15% [2]. Revised pathologic staging on the basis of tumor size less than or equal to 3 cm (stage IA) or greater than 3 cm (stage IB) with no local invasion or nodal metastasis identifies patients with a favorable prognosis. Anatomic resection is the current treatment recommendation for stage I non small cell lung cancer (NSCLC) patients with no clinical evidence of distant metastatic disease and pathologically negative mediastinal lymph nodes. Whereas induction therapy is not routinely used in early stage NSCLC, recent data suggest that adjuvant chemotherapy may improve survival among patients with completely resected NSCLC [3]. The 5-year survival for stages IA and IB, however, remains only 67% and 57%, respectively [4]. Several studies have attempted to define factors that contribute to this poor survival [5 14]. Blood vessel invasion has been evaluated as a prognostic factor with varying results [6 13, 15 20]. The present study examined the association between arterial invasion and survival in 100 patients with stage I NSCLC treated with definitive anatomic resection. Accepted for publication April 20, Address reprint requests to Dr Pechet, Presbyterian-University of Pennsylvania Medical Center, 266 Wright-Saunders Bldg, 39th and Market Sts, Philadelphia, PA 19104; taine.pechet@uphs.upenn.edu. Material and Methods We conducted a retrospective chart review of all 227 patients with NSCLC identified in a tumor registry database at an academic medical center who underwent resection between 1996 and There were 140 patients with stage I cancers, 40 of whom were excluded. Of the remaining 100, none had pleural invasion. Patients who did not undergo anatomic resection (n 8), who had undergone previous lung resection (n 5), or with synchronous or metachronous lesions at presentation (n 4) were excluded. Any patient who received induction or adjuvant chemotherapy or radiation therapy (n 2) was excluded. Seven patients were excluded because of incomplete mediastinal nodal assessment, 1 because pathologic review revealed an adenocarcinoma of metastatic origin, and 13 because of insufficient pathologic material (a minimum of two slides of the original tumor were not available for review). Patients with recurrences were treated with varying protocols of chemotherapy or radiation therapy. All patients underwent pathologic evaluation of their mediastinal lymph nodes (11 sequential mediastinoscopy and thoracotomy, 79 complete intrathoracic nodal dissection [levels 2 to 4, 7 to 9, and 5 to 6 when appropriate], 10 intrathoracic mediastinal nodal sampling). A single surgeon (H.E.C.) performed the 79 mediastinal nodal dissections and the 11 sequential mediastinoscopies. The latter was performed on the basis of preoperative concerns on a case by case basis. These selection criteria yielded 100 patients for analysis. Outpatient and inpatient charts were reviewed for inclusion 2004 by The Society of Thoracic Surgeons /04/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg PECHET ET AL 2004;78: ARTERIAL INVASION AND SURVIVAL IN NSCLC 1749 and exclusion criteria, demographic information, staging, and follow-up data, with mortality confirmed using the social security death index through August Cardiovascular disease was defined as a history of myocardial infarction, coronary artery disease, or hypertension. Pathology slides prepared at the time of surgical resection were reviewed by the single pathologist (J.L.F.) with at least one additional author (S.R.C. or T.T.V.P.). Arterial invasion was defined as the presence of tumor within the lumen of a muscular vessel with a clearly defined internal or external elastic lamina. A positive score required the documentation of arterial invasion in at least two anatomically distinct vessels. In all cases included for review, a minimum of two slides of the original tumor were examined; cases with only a single available slide of the original tumor were excluded. This more stringent requirement for at least two slides with two separate sites of invasion to be considered a positive was chosen to ensure proper classification of all cases. Statistical analyses were performed using SPSS 11.0 (SPSS, Inc, Chicago, IL) and Stata 7.0 (StataCorp, College Station, TX). The groups with and without arterial invasion were compared with the nonparametric Wilcoxon s test for continuous variables and Fisher s exact test for categorical variables. Survival analyses were carried out by means of the Kaplan-Meier approach (log-rank test) and Cox proportional hazards regression. In the multivariable modeling, vascular invasion along with tumor type, stage (or size), and grade were forced into the model irrespective of their statistical significance. Tumor grade was coded with three levels (0 well, 1 moderate, 2 poor) and was used as a continuous variable. The hazard ratio (HR) for this variable corresponds to a comparison of two adjacent grades. For the remaining variables, a stepwise backward elimination algorithm was used, with variables retained if they were significant at the 0.10 level. For 15 patients, the forced expiratory volume in 1 second as a percentage was missing; therefore, this variable was not used during the main modeling analyses, but was only considered for inclusion at the end. This study was reviewed and approved by the institutional review board at Thomas Jefferson University on February 13, Table 1. Patient Characteristics a Variable Arterial Invasion No (n 61) Yes (n 39) p Value Age, mean (SD) 67.5 (8.4) 67.6 (8.2) Sex, n (%) Female 36 (59) 13 (33) Male 25 (41) 26 (67) Race, n (%) White 55 (90) 33 (85) Nonwhite b 6 (10) 6 (15) Cardiovascular disease, n (%) 34 (56) 22 (56) Diabetes, n (%) 9 (15) 9 (23) Creatinine (mg/dl), mean 1.01 (0.35) 0.96 (0.25) (SD) FEV 1 %, mean (SD) 0.75 (0.19) 0.77 (0.16) Bone scan, n (%) 32 (53) 22 (56) Brain scan, n (%) 28 (47) 24 (62) Smoking (pack-years), mean 50.0 (24.9) 53.2 (24.8) (SD) Operation, n (%) Segmentectomy 0 (0) 2 (5) Lobectomy 57 (93) 35 (90) Bilobectomy 3 (5) 1 (3) Pneumonectomy 1 (2) 1 (3) Tumor type, n (%) Adenocarcinoma 26 (43) 14 (36) Squamous cell c 35 (57) 25 (64) Tumor stage, n (%) IA 42 (69) 22 (56) IB 19 (31) 17 (44) Tumor size (cm), mean (SD) 2.9 (1.5) 3.7 (2.2) Tumor size, n (%) cm 23 (38) 10 (26) 2 cm 38 (62) 29 (74) Tumor grade, n (%) Well differentiated 14 (23) 6 (15) Moderately differentiated 23 (38) 8 (21) Poorly differentiated 24 (39) 25 (64) a Age range, 44 to 84 years; creatinine range, 0.5 to 2.6 mg/dl; FEV 1 % range, 0.31 to 1.18 (based on 85 subjects; FEV 1 % was not available for 15 subjects); smoking, 3 nonsmokers (0 pack-years) plus 97 smokers (8 to 110 pack-years); b Includes 1 Asian (in the no vascular invasion group); c Includes 3 spindle tumors (all in the vascular invasion group). FEV 1 % forced expiratory volume in 1 second as a percentage; SD standard deviation. Results Demographics and Tumor Characteristics Table 1 summarizes the patient population for the groups with and without arterial invasion. Arterial invasion was identified in 39 patients, whereas 61 did not have arterial invasion. All patients included in this study were confirmed to have stage I NSCLC by mediastinoscopy or intraoperative lymph node sampling or dissection. Metastatic disease was excluded by clinical or radiographic evaluation, with one half of the patients undergoing brain or bone imaging. All patients underwent complete anatomic resection. There was no significant difference in the proportion of patients who underwent segmentectomy, lobectomy, bilobectomy, or pneumonectomy. The two groups did not differ with respect to age, race, presence of cardiovascular disease, diabetes, renal function, smoking history, or preoperative lung function. The distribution of tumor type was also similar between the patients with or without arterial invasion. The arterial invasion group included relatively more men. Tumors with arterial invasion tended to be larger and more poorly differentiated. There was no significant difference between the proportion of stage IA and stage IB cancers, or the proportion of patients with tumors greater or less than 2 cm. Stage (IA and IB) and the alternative definition
3 1750 PECHET ET AL Ann Thorac Surg ARTERIAL INVASION AND SURVIVAL IN NSCLC 2004;78: Table 2. Unadjusted Mortality Results (n 100) a Variable HR (95% CI) p Value Arterial invasion (yes vs no) 3.50 ( ) Tumor type (squamous cell 0.98 ( ) vs adenocarcinoma) Tumor stage (IB vs IA) 1.03 ( ) Tumor size ( 2 cmvs 1.76 ( ) cm) Tumor grade 0.96 ( ) Age (increment of 10 y) 1.18 ( ) Sex (male vs female) 2.05 ( ) Race (nonwhite vs white) 1.05 ( ) Coronary artery disease 1.37 ( ) (yes vs no) DM (yes vs no) 1.37 ( ) Creatinine (increment of 0.75 ( ) mg/dl) FEV 1 % (increment of 0.1) 0.79 ( ) Bone scan (yes vs no) 1.04 ( ) Brain scan (yes vs no) 0.92 ( ) Smoking (increment of 10 pack-years) 1.09 ( ) a Except for FEV 1 %(n 85; information not available for 15 patients) and brain scan (n 99; brain scan information not available for 1 patient). DM diabetes mellitus; FEV 1 % forced expiratory volume in 1 second as percentage; HR hazard ratio; 95% CI 95% confidence interval. based on size ( 2cmor 2 cm) overlapped substantially. By definition, all stage IB tumors were larger than 2 cm (n 36) as none demonstrated pleural invasion. By contrast, stage IA tumors were equally divided between those 2 cm or less and those more than 2 cm (n 33 and 31, respectively). Complete data, as they relate to recurrence, were available for 64 patients, with a median follow-up of 62 months. From those patients, 16 had arterial invasion and 48 did not. In the group with arterial invasion the median follow-up was 29 months, with 12 (75%) having either distant or local recurrence. In those who had recurrence and arterial invasion, only 2 were alive at 5 years. The remaining 4 patients with arterial invasion who did not have a recurrence were alive at 5 years. For those without arterial invasion, the median follow-up was 69 months, with 9 (19%) having a recurrence. Only 3 patients without arterial invasion who had a recurrence were alive at 5 years, whereas all patients without arterial invasion and recurrence were alive at 5 years. Survival The 100 patients had an overall 5-year survival of 61%. There were 64 stage IA patients with a 62% 5-year survival and 36 stage IB patients with a 58% 5-year survival. Thirty-three patients had tumors less than or equal to 2 cm in size with a 5-year survival of 73%, whereas 67 patients had tumors greater than 2 cm and a 5-year survival of 50%. Table 2 shows the univariate analysis results from Cox proportional hazards regressions. The 5-year survival for all patients showed no correlation with tumor type or grade. The unadjusted estimated HR for arterial invasion was 3.5 (p 0.001). There were 16 deaths in the group without arterial invasion and 26 deaths in those with arterial invasion. The unadjusted mortality rates were 5.1 deaths per 100 person-years and 19.3 deaths per 100 person-years in the two groups, respectively. The Kaplan-Meier survival graph (Fig 1) shows substantially better survival in those without arterial invasion (p 0.001). Patients without arterial invasion had a 73% 5-year survival. By contrast, only 38% of patients with arterial invasion survived 5 years (p 0.001). Median survival was 35 months with arterial invasion. Importantly, the median survival of patients without arterial invasion was not reached at 5 years. The stage I population was further analyzed on the basis of size, using the standard 3-cm criterion for stage IA or IB [4] or a recently proposed 2-cm definition [14, 21]. Table 3 shows two sets of multivariate analysis results from a Cox proportional hazards model (variables included in the model simultaneously). One model corresponds to dividing the patients into those with tumors less than or equal to 3 cm (stage IA) and those greater than 3 cm (stage IB). The second model uses 2 cm as the discriminator. With either model, arterial invasion remained highly significant, with an associated threefold to fourfold increase in mortality. There was virtually no difference in mortality between squamous cell carcinomas and adenocarcinomas. Tumor grade was also not significant. Tumor stage (IA versus IB) showed a small and nonsignificant association with mortality. By contrast, the alternative definition based on tumor size ( 2 cm versus 2 cm) showed a statistically significant (more than twofold) difference in mortality between Fig 1. The Kaplan-Meier survival graph of all 100 patients with stage I non small cell lung cancer. Dotted line overall; solid line no arterial invasion; dashed line arterial invasion.
4 Ann Thorac Surg PECHET ET AL 2004;78: ARTERIAL INVASION AND SURVIVAL IN NSCLC 1751 Table 3. Adjusted Mortality Results (n 85) Variable Using 3-cm Size Using 2-cm Size HR (95% CI) p Value HR (95% CI) p Value Arterial invasion (yes vs no) 3.54 ( ) ( ) Tumor type (squamous cell 1.02 ( ) ( ) vs adenocarcinoma) Tumor stage (IB vs IA) 1.34 ( ) Tumor size ( 2 cmvs 2 cm) 2.59 ( ) Tumor grade 0.78 ( ) ( ) Brain scan (yes vs no) NS 0.47 ( ) FEV 1 % (increment of 0.1) 0.78 ( ) ( ) FEV 1 % forced expiratory volume in 1 second as a percentage; HR hazard ratio; 95% CI 95% confidence interval; NS not significant (p 0.10; variable omitted from final model); small and large tumors. Although significant in the univariate model (Table 2), sex was no longer significant in the multivariate analyses (Table 3). The univariate sex effect (men having higher mortality than women) was mostly a result of the confounding effect of arterial invasion. Arterial invasion was almost twice as common among men as among women (51% versus 27%), and when this difference was adjusted for, the sex effect disappeared. There were 64 patients with stage IA NSCLC and their 5-year survival was 62%. With arterial invasion the 5-year survival was 28% versus 81% without arterial invasion (p 0.001; Fig 2A). This resulted in a 5.8-fold higher risk of dying with arterial invasion than without arterial invasion in the multivariate analysis (p 0.001). The median survival for stage IA patients with arterial invasion was 35 months, and again the median survival was not reached in those patients without arterial invasion. Patients with stage IB cancer had a 5-year survival of 58%. The 5-year survival with (53%) and without (63%) arterial invasion did not reach statistical significance (Fig 2B). This resulted in a 1.7-fold risk of dying with arterial Fig 2. The Kaplan-Meier survival graph of patients with stage IA (A), stage IB (B), with tumors less than or equal to 2 cm (C), or tumors grater than 2 cm (D). Solid lines no arterial invasion; dashed lines arterial invasion.
5 1752 PECHET ET AL Ann Thorac Surg ARTERIAL INVASION AND SURVIVAL IN NSCLC 2004;78: invasion as compared with those without arterial invasion in the multivariate analysis (p 0.359). Patients with tumors less than or equal to 2 cm in size and without arterial invasion had a 5-year survival of 92% versus 31% in patients with arterial invasion (p 0.001; Fig 2C). This resulted in a 19.8-fold higher risk of dying with arterial invasion than without arterial invasion in the multivariate analysis (p 0.006). Median survival was 35 months and was not reached in patients without arterial invasion. A similar difference in survival was noted in patients with tumors greater then 2 cm. Patients without arterial invasion had a 5-year survival of 66% versus 41% in patients with arterial invasion (p 0.02; Fig 2D). This resulted in a 2.9-fold higher risk of dying with arterial invasion than without arterial invasion in the multivariate analysis (p 0.012). Median survival was 32 months with arterial invasion and was not reached at 5 years for patients without arterial invasion. Finally, the hypothesis was tested that arterial invasion has a stronger association with survival in patients with smaller tumors. This was evaluated by adding an interaction term between vascular invasion and tumor stage (or size) to the models shown in Table 3. Although not proven, the hypothesis was qualitatively supported. In the multivariate model with tumor stage, the vascular invasion effect appeared greater among stage IA than among stage IB tumors, with an estimated HR of 5.82 and 1.71, respectively. An even stronger result emerged in the model with tumor size, in which the HR for arterial invasion was 19.8 among tumors 2 cm and 2.85 among tumors more than 2 cm. The interaction, however, did not reach statistical significance in either case (p values for interaction of for arterial invasion and stage, and for arterial invasion and size), a fact that reflects the limited power for detecting interactions with the small sample size of this study. Comment The data presented show that arterial invasion is strongly associated with 5-year survival in patients with stage I NSCLC. This conclusion was shown by both univariate (Table 2) and multivariate (Table 3) analyses. It deserves emphasis that the observed HR of 3.5 to 4 represents a substantially increased risk of dying in patients with arterial invasion. The effect of arterial invasion was independent of all demographic factors and independent of tumor type, stage (IA or IB), and grade (Table 3). Tumor size greater than 2 cm and poor preoperative lung function were independently associated with early mortality. Although not a feature of our initial objective, we chose to explore whether tumor size and arterial invasion are related. The data suggest that in smaller tumors, arterial invasion has a greater effect on survival. The study population was subdivided on the basis of tumor size by two criteria. First, patients were divided into those with tumors greater or less than 3 cm, a demarcation that reflects the current staging system [4]. Alternatively, a 2-cm demarcation was used to subdivide the patients in accordance with recent data suggesting that smaller size is a more sensitive prognostic indicator [14, 21]. In all subgroups, arterial invasion was highly associated with survival (Fig 2). Arterial invasion in stage IA patients was associated with a 53% difference in survival and a 5.8-fold increased risk of dying. Similarly, in patients with stage I tumors less than or equal to 2 cm, arterial invasion predicted a 61% difference in survival and a 19.8-fold increased risk of dying. In patients with tumors greater than 2 cm, arterial invasion predicted a 25% difference in survival (HR 2.85). Overall survival was chosen as the endpoint of this study rather than disease-free survival. This is a potential limitation, and it would be of interest to determine the association between arterial invasion and the incidence of local or distant recurrence. We were not able to evaluate such an association because of incomplete follow-up data on a third of the patients. Also, despite the fact that a single surgeon performed a majority of the operations with complete mediastinal lymph node dissection, a reliable count of the number of lymph nodes originally sampled at each station was also not available. Although not unique to this study, this may contribute to diminished staging accuracy. It would also be of interest to know whether patients with arterial invasion have a higher incidence of nodal metastasis. That is, does arterial invasion indicate more aggressive tumor behavior in general? An important feature of this study is the identification of a prognostic factor readily identifiable on routine pathologic examination. The focus on arterial invasion as a variable eliminates ambiguity resulting from attention to lymphatic or venous invasion. Lymphatics are notoriously difficult to identify with certainty owing to fixation artifacts. The definitive identification of venous channels on routine hematoxylin and eosin stains can be similarly ambiguous in the absence of histochemical delineation of elastic lamellae. By contrast, arteries are readily identified, and the presence of tumor invasion can be accurately assessed. The mechanism whereby arterial invasion dramatically affects survival, however, is not apparent. It can be speculated that arterial invasion is a marker of a more aggressive neoplasm, a feature that relates to survival. Prior studies have examined the relationship between vascular invasion and survival with widely differing conclusions [6, 7, 13, 17, 19, 20]. Several groups have also concluded that vascular invasion portends an adverse prognosis. Many of these studies [9 13, 18, 22], however, are subject to the difficulty inherent in unequivocally identifying venous and lymphatic channels in fixed tissue. Ogawa and colleagues [13] evaluated the effect of blood vessel invasion on survival in stage I NSCLC patients. A significant effect was found with univariate and multivariate analysis. It was not specified, however, whether nonanatomic resections were included in the study population. In addition, both arterial and venous invasion were classed together, and the proportion of the two was not stated. Another Japanese group also reported on prognostic factors in early NSCLC [11, 12]. Arterial invasion was found to predict an adverse sur-
6 Ann Thorac Surg PECHET ET AL 2004;78: ARTERIAL INVASION AND SURVIVAL IN NSCLC 1753 vival in the univariate but not the multivariate analysis. Other studies included advanced stage cancers in their analyses [8, 15, 16, 23]. Macchiarini and associates [9] showed that blood vessel invasion was an independent predictor of survival in patients with stage I NSCLC treated with wedge resection alone. In a subsequent analysis [10], nearly 25% of patients also had nonanatomic resections. Inasmuch as anatomic resection is the current optimal treatment strategy, it is difficult to interpret the relevance of the Pisa group s data. In conclusion, arterial invasion defines a patient population with stage I NSCLC associated with reduced 5-year survival. Clearly, such patients might benefit from additional therapeutic interventions. A prospective trial evaluating the impact of adjuvant chemotherapy on survival in patients with identified arterial invasion is indicated. In light of the recent International Adjuvant Lung Cancer Trial study [3], our data may define a cohort of patients with early stage tumors that would demonstrate increased benefit with adjuvant therapy. Because the effect of arterial invasion is substantial, a targeted trial may be able to expeditiously demonstrate improved survival. Furthermore, the identification of arterial invasion as an adverse prognostic indicator provides a target population with which to correlate genetic and proteonomic analyses. Such an approach may provide information related to the genetic basis of the biologic differences in tumor behavior. References 1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, CA: Cancer J Clin 2003;53: Merrill RM, Henson DE, Barnes M. Conditional survival among patients with carcinoma of the lung [Comment]. Chest 1999;116: Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350: Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111: Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984;54: Spjut HJ, Roper CL, Buthcer HR. Pulmonary cancer and its prognosis: a study of the relationship of certain factors to survival of patients treated by pulmonary resection. Cancer 1961;14: Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983;157: Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988;61: Macchiarini P, Fontanini G, Hardin JM, Pingitore R, Angeletti CA. Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone [Comment]. J Thorac Cardiovasc Surg 1992;104: Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106: Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg 1993;106: Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995;110: Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 1994;73: Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest 2003;124: Kessler R, Gasser B, Massard G, et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 1996;62: Okada M, Sakamoto T, Nishio W, Uchino K, Tsubota N. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension. Cancer 2003;98: Yoshida T, Shirakusa T, Shigematsu N, Ushijima Y, Inokuchi K. Histopathological factors predictive for prognosis of lung cancer. Jpn J Surg 1979;9: Fujisawa T, Yamaguchi Y, Saitoh Y, Hiroshima K, Ohwada H. Blood and lymphatic vessel invasion as prognostic factors for patients with primary resected nonsmall cell carcinoma of the lung with intrapulmonary metastases. Cancer 1995;76: Roberts TE, Hasleton PS, Musgrove C, Swindell R, Lawson RA. Vascular invasion in non-small cell lung carcinoma. J Clin Pathol 1992;45: Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer 1996;78: Lopez-Encuentra A, Duque-Medina JL, Rami-Porta R, de la Camara AG, Ferrando P. Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1,020 patients. Chest 2002;121: Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Katsuda Y. The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection. J Thorac Cardiovasc Surg 1994;108: Yang X, Yan H, Liu H, Xie Y, Hu M, Soimakallio S. Vascular manifestations of small solitary pulmonary masses. Angiographic-pathologic correlations and clinical significance. Invest Radiol 1996;31: INVITED COMMENTARY The report by Pechet and colleagues reviews the potentially important prognostic indicator of arterial invasion in patients with stage I non small cell lung cancer. The study has retrospectively reviewed all patients with stage I cancer operated on within a three-year period. A subset of relatively homogeneous patients (n 100) who had 2004 by The Society of Thoracic Surgeons /04/$30.00 Published by Elsevier Inc doi: /j.athoracsur
Prognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationPrognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients
1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationLung cancer is a prevalent health problem worldwide. It is the leading cause
Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying
More informationPoor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification
CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD
More informationPrognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer
Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationRisk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationImpact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer
Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationThe prognostic significance of central fibrosis of adenocarcinoma
Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationIntraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer
Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki
More informationPrognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution
Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationUpstaging by Vessel Invasion Improves the Pathology Staging System of Non- Small Cell Lung Cancer*
CHEST Original Research Upstaging by Vessel Invasion Improves the Pathology Staging System of Non- Small Cell Lung Cancer* Tomoshi Tsuchiya, MD, PhD; Satoshi Hashizume, MD; Shinji Akamine, MD, PhD; Masashi
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationSurvival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy
Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationInvasion to the visceral pleura is an important component
Diagnosis of Visceral Pleural Invasion by Lung Cancer Using Intraoperative Touch Cytology Yushi Saito, MD, PhD, Yosuke Yamakawa, MD, PhD, Masanobu Kiriyama, MD, PhD, Ichiro Fukai, MD, PhD, Satoshi Kondo,
More informationSurgery remains the mainstay treatment for localized
Surgical Results in T2N0M0 Nonsmall Cell Lung Cancer Patients With Large Tumors 5 cm or Greater in Diameter: What Regulates Outcome? Yasuhiko Ohta, MD, Ryuichi Waseda, MD, Hiroshi Minato, MD, Naoki Endo,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationIncidence of local recurrence and second primary tumors in resected stage I lung cancer
Incidence of local recurrence and second primary tumors in resected stage I lung cancer From 1973 to 1985, 598 patients underwent resection for stage I non-small-cell lung cancer. There were 291 T1 lesions
More informationPleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma
244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationThymic neoplasms are the most common tumors of
Thymic Carcinoma: A Multivariate Analysis of Factors Predictive of Survival in 290 Patients Benny Weksler, MD, Rajeev Dhupar, MD, MBA, Vishal Parikh, BS, Katie S. Nason, MD, MPH, Arjun Pennathur, MD, and
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationTumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer
GENERAL THORACIC ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationLung cancer is the most common cause of cancer-related
Original Article Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita, MD,* Takashi Ohtsuka, MD, PhD,*
More informationSegmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute
Segmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, a Takeshi Mori, PhD, b Koei Ikeda, PhD, b Kentaro Yoshimoto, PhD, b Kenichi
More informationResearch Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
BioMed Research International, Article ID 64568, 6 pages http://dx.doi.org/.55/24/64568 Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationKey words: diameter; lung cancer; lung carcinoma; non-small cell lung cancer; size; staging; T stage; TNM
Diameter of Non-small Cell Lung Cancer Correlates With Long-term Survival* Implications for T Stage Carlos M. Mery, MD, MPH; Anastasia N. Pappas, MSW, MPH; Bryan M. Burt, MD; Raphael Bueno, MD, FCCP; Philip
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationPrognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer
CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationT he increasing incidence and poor survival of patients
710 LUNG CANCER Survival after resection for primary lung cancer: a population based study of 3211 resected patients T-E Strand, H Rostad, B Møller, J Norstein... See end of article for authors affiliations...
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More information